GS1 DSCSA Traceability: Compliance Requirements for Distributors

GS1-Aligned Traceability Solutions: Meeting DSCSA and Supply Chain Transparency Requirements

As of November 27, 2024, wholesale drug distributors must maintain interoperable, electronic traceability systems that comply with the Drug Supply Chain Security Act's Enhanced Drug Distribution Security requirements. GS1 standards—specifically GS1 Global Trade Item Numbers (GTINs), Serial Shipping Container Codes (SSCCs), and Electronic Product Code Information Services (EPCIS)—form the technical foundation for meeting these mandates.

Regulatory Context: DSCSA Serialization and Verification Requirements

The DSCSA, enacted under Title II of the Drug Quality and Security Act (Public Law 113-54), established unit-level traceability requirements for prescription drugs moving through the U.S. supply chain. The statute's serialization provisions went into effect on November 27, 2023, requiring manufacturers to affix product identifiers to drug packages. The verification and traceability requirements that followed one year later mandate that wholesale distributors capture and exchange this data electronically.

Under 21 U.S.C. § 360eee-1(c)(4), wholesale distributors must verify product identifiers before each transaction or aggregation. This verification process requires systems capable of reading GS1 DataMatrix barcodes and processing the four critical data elements: GTIN, serial number, lot number, and expiration date. The FDA's guidance documents specify GS1 standards as the technical framework for encoding and transmitting this information.

GS1 Standards in DSCSA Compliance Architecture

GS1 standards address three distinct compliance requirements under DSCSA:

Product identification: GTINs provide unique identifiers for each drug product at the National Drug Code (NDC) level. Each GTIN corresponds to a specific NDC, packaging configuration, and strength. This standardization enables automated verification across disparate warehouse management and enterprise resource planning systems.

Serialization: GS1 Serial Numbers create unique identities for individual saleable units. When combined with GTINs, these serial numbers enable unit-level tracking from manufacturer through distribution to dispenser. The GS1 DataMatrix barcode encodes this serial number along with lot and expiration data in a machine-readable format.

Transaction documentation: EPCIS 2.0 provides the data exchange standard for Transaction Information, Transaction History, and Transaction Statements (TI/TH/TS) required under 21 U.S.C. § 360eee-1(c)(1). EPCIS events document custody transfers, aggregation relationships, and verification activities in a structured XML or JSON-LD format that downstream trading partners can process without custom integration work.

Implementation Requirements for Wholesale Distributors

Wholesale distributors must implement systems capable of three distinct functions to meet DSCSA's GS1-aligned requirements:

Inbound verification: Scanning and validating product identifiers upon receipt. This requires barcode scanning infrastructure, integration with manufacturer-provided verification router systems (VRS), and exception handling workflows for verification failures.

Data capture and storage: Recording transaction data in EPCIS-compliant format. The average wholesale distributor handles 1,200-8,000 transaction events per day, depending on facility size and product mix. Storage architecture must accommodate seven years of retention per 21 CFR 205.50(f).

Outbound attestation: Generating and transmitting TI/TH/TS documentation in response to downstream requests. Response time requirements are not specified in statute, but industry practice has converged on 24-48 hour response windows for routine verification requests.

Interoperability and the ATP Credential Exchange

GS1 standards enable the Authorized Trading Partner (ATP) verification process required under 21 U.S.C. § 360eee-1(c)(3). Before engaging in a transaction, distributors must verify that their trading partner holds valid state licensure. While DSCSA does not mandate a specific ATP verification method, GS1's Global Location Numbers (GLNs) provide standardized facility identifiers that can be cross-referenced against state board of pharmacy databases.

The FDA has not mandated a centralized ATP registry. As of January 2025, wholesale distributors rely on a combination of state board data, NABP's National Association of Boards of Pharmacy Verified-Accredited Wholesale Distributors (VAWD) program, and proprietary credential exchanges. GS1 GLNs serve as the common identifier across these disparate systems, enabling automated ATP verification workflows.

What ColdChainCheck Data Shows About GS1 Implementation Readiness

Of the 1,275 wholesale drug distributors tracked in ColdChainCheck's directory, FDA registration status provides a baseline indicator of DSCSA compliance posture. 1,234 entities (96.8%) hold current FDA registration under 21 U.S.C. § 360(g)—a prerequisite for handling prescription drugs but not a direct measure of serialization system capability.

The directory's compliance score distribution reveals significant variability in verifiable compliance signals. Only 28 entities (2.2%) score in the "Excellent" tier (80-100 points), indicating full documentation across state licensure, FDA registration, NABP accreditation, and absence of enforcement actions. The 281 entities (22.0%) in the "Good" tier (60-79 points) typically hold broad multi-state licensure and FDA registration but lack NABP accreditation. The 919 entities (72.1%) in the "Fair" tier (40-59 points) represent the majority of the market—licensed distributors with limited cross-referenced compliance signals.

NABP accreditation, tracked for 63 entities in the directory, serves as a proxy for operational maturity. The NABP VAWD program verifies state licensure, physical facility standards, and operational procedures—criteria that correlate with the infrastructure investments required for GS1-aligned serialization systems. However, VAWD accreditation is voluntary and represents only 4.9% of tracked entities, limiting its utility as a sole compliance indicator.

Practical guidance for procurement and QA teams:

• Verify trading partner serialization capability before Q1 2025 product transfers. Use the ColdChainCheck directory to confirm FDA registration and state licensure as baseline qualifications, then request documentation of EPCIS 2.0 compatibility and VRS integration directly from the distributor.

• Cross-reference enforcement history. 73 entities in the directory have FDA recalls on record. Review recall details to assess whether past issues involved data integrity or serialization failures—both indicators of system readiness gaps.

• Document ATP verification workflows. For distributors lacking NABP accreditation, maintain independent verification of state board licensure. ColdChainCheck cross-references 51 state boards of pharmacy; entities with licensure in 15+ states demonstrate operational breadth that may correlate with serialization investment.

• Monitor for enforcement signals. FDA warning letters related to DSCSA violations began appearing in late 2024. ColdChainCheck tracks enforcement actions; entities with clean regulatory records provide lower risk profiles for GS1 traceability compliance.

ColdChainCheck updates FDA registration and state licensure data monthly. For guidance on interpreting compliance scores in the context of DSCSA serialization requirements, see the compliance methodology section.

Disclaimer: This article provides informational content based on publicly available regulatory data and is not legal or compliance advice. Verify all regulatory requirements with qualified legal counsel and the relevant regulatory authorities.

Update: HDA 2025 DSCSA Traceability Seminar: Compliance Roadmap

February 28, 2026

HDA 2025 Traceability Seminar: DSCSA Compliance Roadmap for Distributors

The Healthcare Distribution Alliance held its 2025 Traceability Seminar on March 18-20, outlining updated DSCSA enforcement expectations and operational guidance for wholesale drug distributors navigating the November 2024 Enhanced Drug Distribution Security (EDDS) requirements. FDA representatives clarified ATP verification timelines, VRS onboarding expectations, and enforcement discretion for interoperability gaps—marking the first comprehensive agency guidance since DSCSA traceability went into full effect.

Regulatory Context

The Drug Supply Chain Security Act (DSCSA), enacted under Title II of the Drug Quality and Security Act (Public Law 113-54), established November 27, 2024 as the deadline for Enhanced Drug Distribution Security requirements under 21 U.S.C. § 360eee-1. As of that date, wholesale distributors must verify product identifiers, accept only EPCIS-formatted transaction information, and maintain interoperable systems with trading partners through a Verification Router Service (VRS) or direct ATP queries.

The FDA announced enforcement discretion for specific implementation challenges in its November 2024 guidance document, Compliance Policy for Certain Requirements Under the Drug Supply Chain Security Act (CPG Sec. 160.100). This discretion covers VRS onboarding delays, data exchange format mismatches, and saleable returns processing through November 27, 2025. The HDA seminar provided the first detailed operational interpretation of this enforcement posture.

Key Seminar Takeaways

ATP Verification Timeline Clarification

FDA representatives stated that wholesale distributors must complete ATP verification for new trading partners within 5 business days of the first transaction, not at the point of initial onboarding. This aligns with 21 CFR 205.50(a)(1) but contradicts some industry interpretations that assumed pre-transaction verification. For existing trading partners as of November 27, 2024, distributors have until November 27, 2025 to complete retroactive ATP verification under the enforcement discretion policy.

VRS Onboarding Expectations

The FDA confirmed that distributors unable to access a licensed VRS provider by November 27, 2024 may continue using enhanced verification (direct ATP queries via state board websites or NABP systems) through November 2025. However, distributors must document VRS onboarding attempts, including evidence of requests to VRS providers and reasons for delays. The FDA will not consider lack of VRS availability alone as noncompliance, but distributors must demonstrate good-faith efforts to achieve interoperability.

Saleable Returns Processing

Saleable returns remain the single largest DSCSA compliance gap for mid-sized distributors. Under 21 U.S.C. § 360eee-1(d)(1)(C), wholesale distributors must verify product identifier and transaction history before accepting a saleable return. The HDA seminar outlined a two-track approach: high-value products (biologics, oncology, specialty) require full TI/TS/TP verification before acceptance, while lower-risk products may use enhanced verification (product identifier + ATP check) with full T3 documentation reconciled within 48 hours of receipt.

EPCIS Format Compliance

The FDA stated that wholesale distributors must accept EPCIS 1.2 or EPCIS 2.0 formatted transaction information as of November 27, 2024. Distributors still receiving legacy PDF or EDI formats from upstream trading partners may continue accepting these formats under enforcement discretion, but must document the format mismatch and demonstrate efforts to transition the trading partner to EPCIS. The enforcement discretion does not extend to distributors sending non-EPCIS formats downstream—outbound TI must be EPCIS-compliant.

Impact on Wholesale Distributors

Immediate Operational Changes

Distributors still using legacy verification methods (manual license checks, PDF transaction statements) must document their VRS onboarding status and trading partner transition plans to qualify for enforcement discretion. This requires compliance teams to maintain written records of VRS provider requests, trading partner outreach, and system upgrade timelines. Distributors without these records risk FDA enforcement action during inspections.

Saleable Returns Process Overhaul

The FDA's two-track guidance for saleable returns requires distributors to implement product-tier logic in their receiving systems. High-value products cannot enter inventory without full T3 verification, while lower-risk products may bypass upfront verification if reconciliation occurs within 48 hours. Distributors must define their product-tier criteria and document the decision framework for auditors.

Trading Partner Management

ATP verification for existing trading partners represents the largest compliance lift for mid-sized distributors. Distributors with hundreds of upstream suppliers and downstream pharmacies must complete retroactive ATP verification by November 27, 2025. This requires state board of pharmacy license verification, NABP database checks, or third-party ATP verification services for each entity in the trading partner network.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors tracked in ColdChainCheck's directory, only 63 hold NABP accreditation (formerly VAWD)—a voluntary credential that signals ATP verification capability and DSCSA compliance infrastructure. This 4.9% accreditation rate suggests that most distributors are navigating DSCSA traceability requirements without third-party validation of their systems.

The average compliance score of 51/100 across all tracked entities places the majority (919 entities, or 72%) in the "Fair" tier. This tier indicates basic FDA registration and state licensure, but limited visibility into VRS connectivity, EPCIS readiness, or saleable returns processing capability. Only 28 entities (2.2%) score in the "Excellent" range (80+ points), which requires NABP accreditation, multi-state licensure, and a clean regulatory history.

Practical Guidance for QA and Compliance Teams

• Verify trading partner ATP status before November 27, 2025. Use the ColdChainCheck directory to check state licensure and FDA registration for each distributor in your network. Entities with expired licenses or missing FDA registration cannot qualify as Authorized Trading Partners under 21 U.S.C. § 360eee-1(a)(2).

• Prioritize NABP-accredited distributors for high-value product channels. The 63 NABP-accredited entities in ColdChainCheck's database have undergone third-party audit of their DSCSA compliance systems, including VRS connectivity and transaction documentation processes. For biologics, oncology, and specialty products requiring full T3 verification on saleable returns, NABP accreditation reduces ATP verification overhead.

• Document VRS onboarding attempts for non-accredited trading partners. If your upstream suppliers or downstream customers are not NABP-accredited and do not appear in a licensed VRS provider's network, document their onboarding status in your trading partner files. The FDA's enforcement discretion requires evidence of good-faith VRS transition efforts—not just evidence that the trading partner holds valid licenses.

• Cross-reference FDA registration with state licensure. ColdChainCheck tracks 1,234 entities (96.8%) with active FDA registration, but state licensure data reveals compliance gaps: 25,665 active state licenses across 35,146 total license records represents a 73% active rate. Distributors operating in states where they lack current licensure cannot serve as Authorized Trading Partners in those jurisdictions, regardless of FDA registration status.

ColdChainCheck updates state licensure data monthly from 51 state boards of pharmacy and cross-references FDA establishment registration quarterly. For DSCSA traceability guidance and ATP verification workflows, see the compliance guides section.

Disclaimer: This article is for informational purposes only and does not constitute legal or regulatory advice. Wholesale distributors should consult qualified legal counsel and verify all regulatory requirements with the FDA and applicable state boards of pharmacy.